Capital Hill Event: Drug Pricing Policy Prescriptions for 2020

On September 25, 2019, the American Consumer Institute held a policy briefing called “Pricing Policy Prescriptions for 2020: The Good, The Bad, and The Ugly.” The event included guest speaker John Fund, along with the following policy experts: Krisztina Pusok, Director of Policy and Research at the American Consumer Institute (moderating); Robert Graboyes is a Senior […]

Drug Pricing Policy Prescriptions for 2020: The Good, The Bad, and The Ugly — September 25, 2019

Senate Russell Office Building Featured Keynote Speaker: John Fund Topic: Escalating drug prices are generating a fierce political and policy debate. Join the American Consumer Institute on September 25th for a distinguished panel of experts who will discuss recent proposals put forth in Congress and the White House to address increasing prescription drug costs. Hear […]

Coalition Calls for Increased Generic Drug Competition

While the Lower Health Care Costs Act is intended to increase competition and patient access to lower cost medicines, section 205 of the bill needs to address FDA concerns about the “parking” of generic applications. We believe generic manufacturers need to launch new medications into the market as soon as possible after approval. However, as […]

ACI in the Wall Street Journal: Vaping Ban Will Send Smokers Back to the Pack

Public health officials should thoroughly investigate the roots of the recent surge in respiratory illnesses. But before pinning the blame on legitimate e-cigarette manufacturers—and before banning their products—lawmakers should examine how their own heavy-handed approach to overtaxing and overregulating has encouraged consumers to develop dangerous homemade concoctions and buy unregulated counterfeits from the black market […]

Real Clear Health: Drug Importation — High Risk, Low Reward

It’s tempting to think that legalizing drug importation would immediately give U.S. consumers access to medicines at the prices available in other developed countries. In reality, however, the Safe Importation Action Plan would expose American consumers to significant health risks while achieving meager cost reductions, if any at all. Visit Real Clear Health to lean […]

Townhall: Importing Drugs from Canada Would Kill Innovation and Could Cost Lives

In partnership with the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS) has recently proposed that certain pharmaceuticals should be cleared for import from Canada. Although the proposal seeks to lower prices for consumers, it poses critical unintended risks to both American businesses and patients. To read why, visit Townhall.

Open the Canadian Border for Drug Imports, and Dangerous Counterfeits will Follow

In an effort to reverse the continuing rise of prescription drug prices, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) are mulling the idea of allowing drug imports from Canada. Their so-called “Safe Importation Action Plan,” however, is a misnomer—the policy could expose countless Americans to potentially deadly […]

Inside Sources: What Politicians Get Wrong About the Economics of Drug Importation

Last month, federal officials announced the Safe Importation Action Plan to legalize the importation of foreign drug products, including from Canada. However, the biggest concern with is proposal is that drug importation will expose American patients to unsafe, adulterated and counterfeit medicines from all over the world. To learn more, you can read this op-ed […]